Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Prospective acceleration of parallel RF transmission-based 3D chemical exchange saturation transfer imaging with compressed sensing.

Heo HY, Xu X, Jiang S, Zhao Y, Keupp J, Redmond KJ, Laterra J, van Zijl PCM, Zhou J.

Magn Reson Med. 2019 Nov;82(5):1812-1821. doi: 10.1002/mrm.27875. Epub 2019 Jun 17.

PMID:
31209938
2.

Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.

Ma D, Liu S, Lal B, Wei S, Wang S, Zhan D, Zhang H, Lee RS, Gao P, Lopez-Bertoni H, Ying M, Li JJ, Laterra J, Wilson MA, Xia S.

Cancer Res. 2019 May 15;79(10):2697-2708. doi: 10.1158/0008-5472.CAN-18-3125. Epub 2019 Mar 21.

PMID:
30898840
3.

The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma.

Xu X, Xu J, Knutsson L, Liu J, Liu H, Li Y, Lal B, Laterra J, Artemov D, Liu G, van Zijl PCM, Chan KWY.

Magn Reson Med. 2019 Jun;81(6):3798-3807. doi: 10.1002/mrm.27683. Epub 2019 Feb 22.

PMID:
30793789
4.

Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons.

Xue Y, Zhan X, Sun S, Karuppagounder SS, Xia S, Dawson VL, Dawson TM, Laterra J, Zhang J, Ying M.

Stem Cells Transl Med. 2019 Feb;8(2):112-123. doi: 10.1002/sctm.18-0036. Epub 2018 Nov 1.

5.

Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage.

Shen CJ, Kummerlowe MN, Redmond KJ, Martinez-Gutierrez JC, Usama SM, Holdhoff M, Grossman SA, Laterra JJ, Strowd RE, Kleinberg LR.

Adv Radiat Oncol. 2018 Jul 10;3(4):582-590. doi: 10.1016/j.adro.2018.06.005. eCollection 2018 Oct-Dec.

6.

Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.

Jiang S, Eberhart CG, Lim M, Heo HY, Zhang Y, Blair L, Wen Z, Holdhoff M, Lin D, Huang P, Qin H, Quinones-Hinojosa A, Weingart JD, Barker PB, Pomper MG, Laterra J, van Zijl PCM, Blakeley JO, Zhou J.

Clin Cancer Res. 2019 Jan 15;25(2):552-561. doi: 10.1158/1078-0432.CCR-18-1233. Epub 2018 Oct 26.

PMID:
30366937
7.

Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.

Tung B, Ma D, Wang S, Oyinlade O, Laterra J, Ying M, Lv SQ, Wei S, Xia S.

BMC Cancer. 2018 Oct 22;18(1):1025. doi: 10.1186/s12885-018-4874-8.

8.

CEST MRI of 3-O-methyl-D-glucose uptake and accumulation in brain tumors.

Sehgal AA, Li Y, Lal B, Yadav NN, Xu X, Xu J, Laterra J, van Zijl PCM.

Magn Reson Med. 2019 Mar;81(3):1993-2000. doi: 10.1002/mrm.27489. Epub 2018 Sep 11.

PMID:
30206994
9.

Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival.

Lopez-Bertoni H, Kozielski KL, Rui Y, Lal B, Vaughan H, Wilson DR, Mihelson N, Eberhart CG, Laterra J, Green JJ.

Nano Lett. 2018 Jul 11;18(7):4086-4094. doi: 10.1021/acs.nanolett.8b00390. Epub 2018 Jun 28.

10.

INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.

Ames HM, Rooper LM, Laterra JJ, Eberhart CG, Rodriguez FJ.

J Neuropathol Exp Neurol. 2018 May 1;77(5):374-382. doi: 10.1093/jnen/nly014.

11.

Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration.

Oyinlade O, Wei S, Lal B, Laterra J, Zhu H, Goodwin CR, Wang S, Ma D, Wan J, Xia S.

Oncogene. 2018 May;37(20):2615-2629. doi: 10.1038/s41388-018-0138-y. Epub 2018 Feb 26.

12.

Language Mapping Using T2-Prepared BOLD Functional MRI in the Presence of Large Susceptibility Artifacts-Initial Results in Patients With Brain Tumor and Epilepsy.

Hua J, Miao X, Agarwal S, Bettegowda C, Quiñones-Hinojosa A, Laterra J, Van Zijl PCM, Pekar JJ, Pillai JJ.

Tomography. 2017 Jun;3(2):105-113. doi: 10.18383/j.tom.2017.00006.

13.

TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents.

Coulter JB, Lopez-Bertoni H, Kuhns KJ, Lee RS, Laterra J, Bressler JP.

Epigenetics. 2017;12(10):854-864. doi: 10.1080/15592294.2017.1359452. Epub 2017 Nov 27.

14.

Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.

Salas Fragomeni RA, Menke JR, Holdhoff M, Ferrigno C, Laterra JJ, Solnes LB, Javadi MS, Szabo Z, Pomper MG, Rowe SP.

Clin Nucl Med. 2017 Oct;42(10):e433-e435. doi: 10.1097/RLU.0000000000001769.

15.

Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas.

Jiang S, Eberhart CG, Zhang Y, Heo HY, Wen Z, Blair L, Qin H, Lim M, Quinones-Hinojosa A, Weingart JD, Barker PB, Pomper MG, Laterra J, van Zijl PCM, Blakeley JO, Zhou J.

Eur J Cancer. 2017 Sep;83:9-18. doi: 10.1016/j.ejca.2017.06.009. Epub 2017 Jul 10.

16.

Neuro-Oncology: Current Concepts and Emerging Therapeutics.

Nabors B, Laterra J.

Neurotherapeutics. 2017 Apr;14(2):253-255. doi: 10.1007/s13311-017-0529-8. No abstract available.

17.

The cancer stem cell phenotype: You can't win until you learn how to lose it.

Lopez-Bertoni H, Laterra J.

Mol Cell Oncol. 2015 Jan 23;2(3):e989760. doi: 10.4161/23723556.2014.989760. eCollection 2015 Jul-Sep.

18.

Investigational new drugs for brain cancer.

Staedtke V, Bai RY, Laterra J.

Expert Opin Investig Drugs. 2016 Aug;25(8):937-56. doi: 10.1080/13543784.2016.1182497. Epub 2016 May 17. Review.

19.

Cancer Stem Cells: Dynamic Entities in an Ever-Evolving Paradigm.

Lopez-Bertoni H, Li Y, Laterra J.

Biol Med (Aligarh). 2015 Nov;7(Suppl 2). pii: 001. Epub 2014 Nov 11.

20.

Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems.

Goodwin CR, Woodard CL, Zhou X, Pan J, Olivi A, Xia S, Bettegowda C, Sciubba DM, Pevsner J, Zhu H, Laterra J.

Transl Oncol. 2016 Apr;9(2):124-129. doi: 10.1016/j.tranon.2016.02.001.

21.

Regulation of Glioblastoma Tumor-Propagating Cells by the Integrin Partner Tetraspanin CD151.

Tilghman J, Schiapparelli P, Lal B, Ying M, Quinones-Hinojosa A, Xia S, Laterra J.

Neoplasia. 2016 Mar;18(3):185-98. doi: 10.1016/j.neo.2016.02.003.

22.

Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform.

Lesniak WG, Oskolkov N, Song X, Lal B, Yang X, Pomper M, Laterra J, Nimmagadda S, McMahon MT.

Nano Lett. 2016 Apr 13;16(4):2248-53. doi: 10.1021/acs.nanolett.5b04517. Epub 2016 Mar 1.

23.

Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells.

Lopez-Bertoni H, Lal B, Michelson N, Guerrero-Cázares H, Quiñones-Hinojosa A, Li Y, Laterra J.

Oncogene. 2016 Sep 15;35(37):4903-13. doi: 10.1038/onc.2016.22. Epub 2016 Feb 22.

24.

A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis.

Sun H, Luo L, Lal B, Ma X, Chen L, Hann CL, Fulton AM, Leahy DJ, Laterra J, Li M.

Nat Commun. 2016 Feb 4;7:10339. doi: 10.1038/ncomms10339.

25.

Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma Patients.

Xu X, Yadav NN, Knutsson L, Hua J, Kalyani R, Hall E, Laterra J, Blakeley J, Strowd R, Pomper M, Barker P, Chan K, Liu G, McMahon MT, Stevens RD, van Zijl PC.

Tomography. 2015 Dec;1(2):105-114.

26.

Extraneural Glioblastoma Multiforme Vertebral Metastasis.

Goodwin CR, Liang L, Abu-Bonsrah N, Hdeib A, Elder BD, Kosztowski T, Bettegowda C, Laterra J, Burger P, Sciubba DM.

World Neurosurg. 2016 May;89:578-582.e3. doi: 10.1016/j.wneu.2015.11.061. Epub 2015 Dec 15. Review.

27.

Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting.

Lukas RV, Wainwright DA, Laterra JJ.

Future Oncol. 2016 Jan;12(2):143-7. doi: 10.2217/fon.15.299. Epub 2015 Nov 30.

28.

Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer.

Xu X, Chan KW, Knutsson L, Artemov D, Xu J, Liu G, Kato Y, Lal B, Laterra J, McMahon MT, van Zijl PC.

Magn Reson Med. 2015 Dec;74(6):1556-63. doi: 10.1002/mrm.25995. Epub 2015 Sep 25.

29.

Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.

Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J.

Neuro Oncol. 2016 Apr;18(4):507-17. doi: 10.1093/neuonc/nov171. Epub 2015 Aug 27.

30.

Identification of Global DNA Methylation Signatures in Glioblastoma-Derived Cancer Stem Cells.

Lee EJ, Rath P, Liu J, Ryu D, Pei L, Noonepalle SK, Shull AY, Feng Q, Litofsky NS, Miller DC, Anthony DC, Kirk MD, Laterra J, Deng L, Xin HB, Wang X, Choi JH, Shi H.

J Genet Genomics. 2015 Jul 20;42(7):355-71. doi: 10.1016/j.jgg.2015.06.003. Epub 2015 Jun 24.

31.

Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature.

Khattab MH, Marciscano AE, Lo SS, Lim M, Laterra JJ, Kleinberg LR, Redmond KJ.

Case Rep Oncol Med. 2015;2015:431819. doi: 10.1155/2015/431819. Epub 2015 Jun 23.

32.

Parallel reconstruction in accelerated multivoxel MR spectroscopy.

Boer VO, Klomp DW, Laterra J, Barker PB.

Magn Reson Med. 2015 Sep;74(3):599-606. doi: 10.1002/mrm.25718. Epub 2015 Jun 17.

33.

Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.

Strowd RE, Salvatori R, Laterra JJ.

J Oncol Pharm Pract. 2016 Jun;22(3):517-22. doi: 10.1177/1078155215569556. Epub 2015 Jan 23.

PMID:
25616657
34.

Multi-echo length and offset VARied saturation (MeLOVARS) method for improved CEST imaging.

Song X, Xu J, Xia S, Yadav NN, Lal B, Laterra J, Bulte JW, van Zijl PC, McMahon MT.

Magn Reson Med. 2015 Feb;73(2):488-96. doi: 10.1002/mrm.25567. Epub 2014 Dec 16.

35.

DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2.

Lopez-Bertoni H, Lal B, Li A, Caplan M, Guerrero-Cázares H, Eberhart CG, Quiñones-Hinojosa A, Glas M, Scheffler B, Laterra J, Li Y.

Oncogene. 2015 Jul 23;34(30):3994-4004. doi: 10.1038/onc.2014.334. Epub 2014 Oct 20.

36.

Kruppel-like factor-9 (KLF9) inhibits glioblastoma stemness through global transcription repression and integrin α6 inhibition.

Ying M, Tilghman J, Wei Y, Guerrero-Cazares H, Quinones-Hinojosa A, Ji H, Laterra J.

J Biol Chem. 2014 Nov 21;289(47):32742-56. doi: 10.1074/jbc.M114.588988. Epub 2014 Oct 6.

37.

Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons.

Sagal J, Zhan X, Xu J, Tilghman J, Karuppagounder SS, Chen L, Dawson VL, Dawson TM, Laterra J, Ying M.

Stem Cells Transl Med. 2014 Aug;3(8):888-98. doi: 10.5966/sctm.2013-0213. Epub 2014 Jun 5.

38.

Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.

Sun P, Xia S, Lal B, Shi X, Yang KS, Watkins PA, Laterra J.

BMC Cancer. 2014 Jun 4;14:401. doi: 10.1186/1471-2407-14-401.

39.

HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells.

Tilghman J, Wu H, Sang Y, Shi X, Guerrero-Cazares H, Quinones-Hinojosa A, Eberhart CG, Laterra J, Ying M.

Cancer Res. 2014 Jun 1;74(11):3168-79. doi: 10.1158/0008-5472.CAN-13-2103. Epub 2014 Apr 7.

40.

Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model.

Hong X, Liu L, Wang M, Ding K, Fan Y, Ma B, Lal B, Tyler B, Mangraviti A, Wang S, Wong J, Laterra J, Zhou J.

Neuro Oncol. 2014 Jun;16(6):856-67. doi: 10.1093/neuonc/not245. Epub 2013 Dec 22.

41.

Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling.

Woodard CL, Goodwin CR, Wan J, Xia S, Newman R, Hu J, Zhang J, Hayward SD, Qian J, Laterra J, Zhu H.

PLoS One. 2013 Sep 2;8(9):e72671. doi: 10.1371/journal.pone.0072671. eCollection 2013.

42.

In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells.

Rath P, Lal B, Ajala O, Li Y, Xia S, Kim J, Laterra J.

Transl Oncol. 2013 Apr;6(2):104-11. Epub 2013 Apr 1.

43.

Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement.

Zhou J, Zhu H, Lim M, Blair L, Quinones-Hinojosa A, Messina SA, Eberhart CG, Pomper MG, Laterra J, Barker PB, van Zijl PC, Blakeley JO.

J Magn Reson Imaging. 2013 Nov;38(5):1119-28. doi: 10.1002/jmri.24067. Epub 2013 Feb 25.

44.

Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms.

Zhang Y, Pullambhatla M, Laterra J, Pomper MG.

Mol Imaging. 2012 Nov-Dec;11(6):499-506.

45.

Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.

Rosca EV, Lal B, Koskimaki JE, Popel AS, Laterra J.

Anticancer Drugs. 2012 Aug;23(7):706-12. doi: 10.1097/CAD.0b013e3283531041.

46.

Regulation of glioblastoma multiforme stem-like cells by inhibitor of DNA binding proteins and oligodendroglial lineage-associated transcription factors.

Wu Y, Richard JP, Wang SD, Rath P, Laterra J, Xia S.

Cancer Sci. 2012 Jun;103(6):1028-37. doi: 10.1111/j.1349-7006.2012.02260.x. Epub 2012 Apr 4.

47.

EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.

Wang SD, Rath P, Lal B, Richard JP, Li Y, Goodwin CR, Laterra J, Xia S.

Oncogene. 2012 Dec 13;31(50):5132-43. doi: 10.1038/onc.2012.16. Epub 2012 Feb 6.

48.

Cancer stem cells: distinct entities or dynamically regulated phenotypes?

Li Y, Laterra J.

Cancer Res. 2012 Feb 1;72(3):576-80. doi: 10.1158/0008-5472.CAN-11-3070. Review.

49.

Evaluation of radiation necrosis and malignant glioma in rat models using diffusion tensor MR imaging.

Wang S, Chen Y, Lal B, Ford E, Tryggestad E, Armour M, Yan K, Laterra J, Zhou J.

J Neurooncol. 2012 Mar;107(1):51-60. doi: 10.1007/s11060-011-0719-x. Epub 2011 Sep 27.

50.

PTEN reconstitution alters glioma responses to c-Met pathway inhibition.

Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J.

Anticancer Drugs. 2011 Oct;22(9):905-12. doi: 10.1097/CAD.0b013e3283484750.

Supplemental Content

Loading ...
Support Center